Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta GlobeNewswire - Mon Dec 29, 7:30AM CST

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of...

RARE : 19.72 (-42.32%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Dec 19, 3:30PM CST

NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 19.72 (-42.32%)
Ultragenyx to Participate in Investor Conferences in December GlobeNewswire - Mon Nov 24, 3:30PM CST

NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 19.72 (-42.32%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 21, 3:30PM CST

NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 19.72 (-42.32%)
Ultragenyx: Q3 Earnings Snapshot AP - Tue Nov 4, 3:13PM CST

Ultragenyx: Q3 Earnings Snapshot

RARE : 19.72 (-42.32%)
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update GlobeNewswire - Tue Nov 4, 3:05PM CST

Third quarter total revenue of $160 million,  Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670...

RARE : 19.72 (-42.32%)
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences GlobeNewswire - Tue Nov 4, 3:01PM CST

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55...

RARE : 19.72 (-42.32%)
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups GlobeNewswire - Thu Oct 30, 7:00AM CDT

NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the  Aurora study (NCT07157254) evaluating the...

RARE : 19.72 (-42.32%)
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update GlobeNewswire - Tue Oct 28, 3:30PM CDT

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 19.72 (-42.32%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Oct 24, 3:30PM CDT

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 19.72 (-42.32%)

Barchart Exclusives

The Next Two Years Will Belong To Breakups: Investors Who Miss It Will Miss the Cycle Barchart - 1 hour ago
Alpha is not gone. It is just stuck inside companies that forgot what business they are really in. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot